Applied Biosystems' Good Genes Boost Stock 56% In 2000; Index Ahead 29%
This article was originally published in The Gray Sheet
Executive Summary
The untapped possibilities of genetic analysis for early stage detection of disease combined with a nearly completed effort to map the human genome helped breathe new life into the diagnostics sector in 2000, led by Applera Corp. (formerly PE Corp.) and its two component business units, Applied Biosystems and Celera Genomics.
You may also be interested in...
Abbott Lands FISH Technology For Cancer DNA Probe Tests With Vysis Buy
Abbott Laboratories is expanding its molecular diagnostics offerings to include tests for cancer and other genetic diseases through the $355 mil. cash acquisition of Vysis under a definitive agreement, announced Oct. 24.
Abbott Lands FISH Technology For Cancer DNA Probe Tests With Vysis Buy
Abbott Laboratories is expanding its molecular diagnostics offerings to include tests for cancer and other genetic diseases through the $355 mil. cash acquisition of Vysis under a definitive agreement, announced Oct. 24.
B&L Eyes Zyoptix Per-Procedure Fees To Recoup LASIK Royalties To Visx
Bausch & Lomb will look to its Zyoptix eye diagnostic system to eventually offset royalty payments to LASIK competitor Visx.